Generex Biotechnology Corp. (fka GNBTQ)

[Solar_Express]

initiate human clinical trials in 3 to 5 months depending on regulatory agency requirements. We have vaccinated over 300 people with Ii-Key vaccines to demonstrate their safety and their ability to activate the immune response against peptide epitopes. As a public service to expedite the review of the Ii-Key vaccine technology by interested parties, we are providing a summary of safety on our Ii-Key development program from both published peer-reviewed literature as well as from our clinical investigator brochures on our website at Generex.com.”

https://generex.com/covid-19